Vanguard Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.65M Hold
3,417,223
– – ﹤0.01% 2841
2026
Q2
$13.5M Buy
3,417,223
+124,089
+4% +$451K ﹤0.01% 2659
2026
Q1
$10.1M Hold
3,293,134
– – ﹤0.01% 2724

Other funds holding ELDN

Vanguard Capital Management's ELDN Position: Q3 2026 in Review

Vanguard Capital Management held its Eledon Pharmaceuticals (ELDN) position steady in Q3 2026 at 3,417,223 shares worth $8.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2841.

Vanguard Capital Management first reported a position in ELDN in Q1 2026 and has held it in 3 quarters since. The position peaked at $13.5M in Q2 2026. 155 funds tracked by Wall St. Rank hold ELDN as of Q3 2026.

  • Vanguard Capital Management held 3,417,223 shares of Eledon Pharmaceuticals worth $8.65M as of Q3 2026.
  • Vanguard Capital Management left its Eledon Pharmaceuticals share count unchanged in Q3 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2841 holding.
  • Vanguard Capital Management first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Eledon Pharmaceuticals position peaked at $13.5M in Q2 2026.
  • 155 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.